Terra Chips Maker Hain Celestial Seeks Strategic Options For Business, Announces CEO Transition, Stock Tanks
The company reported a third-quarter FY25 revenue decline of 11% year-on-year to $390.35 million, missing the analyst consensus estimate of $4411.62 million. Adjusted EPS of $0.07 missed the consensus estimate of $0.13.
Organic net sales from North America decreased 10% Y/Y, primarily driven by lower sales in snacks and baby & kids.
Also Read: McDonald's Stumbles On Weak Traffic, Despite Margin Gains And Analyst Optimism
International organic sales gained 0.5%, driven by growth in meal prep and baby & kids and the supply chain recovery from the service issues discussed last quarter.
The Terra Chips maker adjusted gross margin for the quarter contracted 50 basis points Y/Y to 21.8%. The operating loss for the quarter was $121.1 million versus a loss of $27.9 million last year.
Adjusted EBITDA was $34 million compared to $44 million in the prior year period. The adjusted EBITDA margin was 8.6%, compared to 10% in the prior year.
The company held $44.4 million in cash and equivalents as of March 31, 2025. Operating cash flow for the quarter was $5 million, with a free cash flow of $(2) million.
Net debt at the end of the fiscal second quarter was $665 million compared to $690 million at the beginning of the fiscal year.
CEO Transition
Hain announced that Wendy Davidson will depart as President, Chief Executive Officer and member of the Board of Directors, effective Wednesday.
"We are disappointed with our third quarter results, which fell far short of our expectations primarily due to worse-than-expected performance in North America," stated Interim President and CEO Alison Lewis.
Business Strategic Review
Hain also said that the Board is conducting a comprehensive review of the company's portfolio with the assistance of its independent financial advisor, Goldman Sachs & Co.
"Going forward, we are focused on five key drivers for improving value: simplifying our business and reducing overhead spending, accelerating renovation and innovation in our brands, implementing strategic revenue growth management and pricing actions, driving operational productivity and working capital reduction, and strengthening our digital capabilities."
Outlook For FY25
Hain Celestial expects FY25 organic net sales to decline 5% – 6%.
Adjusted EBITDA is expected to be approximately $125 million. Gross margin is expected to be approximately 21.5%.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
Nordson (NDSN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Manufacturing company Nordson (NASDAQ:NDSN) will be reporting results this Wednesday afternoon. Here's what to look for. Nordson beat analysts' revenue expectations by 1.1% last quarter, reporting revenues of $682.9 million, up 5% year on year. It was a satisfactory quarter for the company, with EPS guidance for next quarter topping analysts' expectations but organic revenue in line with analysts' estimates. Is Nordson a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Nordson's revenue to grow 9.1% year on year to $721.7 million, improving from the 2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $2.63 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Nordson has missed Wall Street's revenue estimates three times over the last two years. Looking at Nordson's peers in the professional tools and equipment segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Lincoln Electric delivered year-on-year revenue growth of 6.6%, beating analysts' expectations by 5.1%, and Hillman reported revenues up 6.2%, topping estimates by 2.6%. Lincoln Electric traded up 7.8% following the results while Hillman was also up 22.9%. Read our full analysis of Lincoln Electric's results here and Hillman's results here. There has been positive sentiment among investors in the professional tools and equipment segment, with share prices up 4.8% on average over the last month. Nordson's stock price was unchanged during the same time and is heading into earnings with an average analyst price target of $251.80 (compared to the current share price of $215.93). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
Analog Devices (ADI) Q2 Earnings: What To Expect
Manufacturer of analog chips Analog Devices (NASDAQ:ADI) will be reporting results this Wednesday before market hours. Here's what to look for. Analog Devices beat analysts' revenue expectations by 5.2% last quarter, reporting revenues of $2.64 billion, up 22.3% year on year. It was a very strong quarter for the company, with a beat of analysts' EPS estimates and an impressive beat of analysts' adjusted operating income estimates. Is Analog Devices a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Analog Devices's revenue to grow 19.5% year on year to $2.76 billion, a reversal from the 24.9% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.95 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Analog Devices has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 1.7% on average. Looking at Analog Devices's peers in the analog semiconductors segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Impinj's revenues decreased 4.5% year on year, beating analysts' expectations by 4.3%, and Universal Display reported revenues up 8.4%, topping estimates by 6.1%. Impinj traded up 26.2% following the results while Universal Display's stock price was unchanged. Read our full analysis of Impinj's results here and Universal Display's results here. Investors in the analog semiconductors segment have had steady hands going into earnings, with share prices flat over the last month. Analog Devices is down 3.5% during the same time and is heading into earnings with an average analyst price target of $254.16 (compared to the current share price of $232.10). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Yahoo
an hour ago
- Yahoo
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program
SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ('CytoMed' or 'Company'), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of blood and solid cancers, is pleased to announce that it entered into an At-the-Market Sales Agreement (the 'Sales Agreement') with R.F. Lafferty & Co., Inc. (the 'Agent'), as the sales agent. Pursuant to the Sales Agreement, the Company may offer and sell through the Agent, ordinary shares, no par value (the 'Shares'), of the Company having an aggregate value of up to U.S.$4,304,945. The timing and amount of any sales of Shares under the ATM program will be determined by the Company at its discretion, depending on market conditions and the Company's capital requirements. The Company intends to use the proceeds from the ATM program for general corporate purposes, which may include business diversification and development initiatives and capital expenditures. We may also use a portion of the net proceeds from this offering to appoint professionals to explore potential acquisitions or strategic investments in complementary businesses or technologies. However as of the date of this press release, the Company has not entered into any definitive agreements. The Company will provide updates to shareholders as additional information becomes available. In the event that any net proceeds are not immediately applied, we may temporarily hold them as cash or deposit them in banks. For information, the Company's newly acquired cord blood bank has seen approximately 2,500 new customer sign-ups since acquiring it in August 2024, contributing to revenue in 2025. About CytoMed Therapeutics Limited (CytoMed) Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore's leading research and development agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit and follow us on Twitter ('X') @CytomedSG, on LinkedIn, and Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof. Contact : CytoMed Therapeutics Limitedenquiry@ : Evelyn Tan, Chief Corporate Officer
